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INTRODUCTION
Diabetic men are at higher risk for suffering from erectile dysfunction than the general population (Feldman et al., 1994; Martín-Morales et al., 2001 ).
Erectile function depends on the relaxant capacity of penile smooth muscle, which is required for vasodilation and cavernosal expansion leading to blood accumulation and penile erection (Saenz de Tejada et al., 1991) . Human penile smooth muscle tone is regulated by a tight balance between contractile and relaxant mediators. Alteration of the physiological mechanisms of tone regulation leading to a disbalance that favours contractile pathways and/or reduce relaxation could cause the inability to achieve an adequate erection.
Prostanoids participate in the regulation of penile smooth muscle tone.
EP receptors mediate relaxation while the TP receptors mediate contraction in human corpus cavernosum tissue (Angulo et al., 2002) . Prostaglandin E 1 (PGE 1 ) has been shown to produce trabecular smooth muscle relaxation and penile erection, and has been widely used as intracavernosal therapy for impotence (Porst, 1996) . PGE 1 has a short half-life but it may be converted to prostaglandin E 0 (PGE 0 ), which is an active metabolite with similar properties to PGE 1 but with a longer half-life (Ney et al., 1991) .
Prostanoid-driven pathways can be altered by diabetes. Indeed, excessive production of contractile prostanoids (Davi et al., 1997; Koltai et al., 1990) or enhanced contractile responses to prostanoids have been described (Hattori et al., 1999; McCarty, 1998) .
Several molecular mechanisms have been proposed to be responsible for the vascular alterations associated to diabetes, including hyperactivation of JPET #108597
METHODS

Human corpus cavernosum tissues.
Human corpus cavernosum specimens, were obtained from impotent diabetic and non diabetic men at the time of penile prosthesis insertion after giving informed consent. Some specimens were also collected from organ donors.
Protocols were approved by the local Ethics Committee. Tissues were maintained at 4-6ºC in M-400 solution (composition per 100 ml: manitol, 4.19 g; , 0.084 g) until used, which was between 2 and 16 hours from extraction (Angulo et al., 2002) .
Organ chamber studies.
Strips of corpus cavernosum tissue (3 x 3 x 7 mm) were immersed in 8 ml organ chambers containing physiological salt solution (PSS) of the following composition (mM): NaCl 119, KCl 4.6, CaCl 2 1.5, MgCl 2 1.2, NaHCO 3 24.9, glucose 11, KH 2 PO 4 1.2, EDTA 0.027 at 37º C continuously bubbled with 95% O 2 /5% CO 2 mixture to maintain a pH of 7.4. Each tissue strip was incrementally stretched to optimal isometric tension, as determined by maximal contractile response to 1 µM phenylephrine (Azadzoi et al., 1992; Kim et al., 1991) .
Contractile responses were evaluated by adding increasing cumulative concentrations of compounds on unstimulated strips. For the relaxation studies, tissues were contracted with 0.5 -3 µM phenylephrine and relaxation responses were evaluated by cumulative additions of compounds to the chambers.
Measurement of cyclic AMP in human corpus cavernosum tissue.
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Corpus cavernosum strips were immersed in 8 ml organ chambers containing PSS, maintained at 37ºC and aerated with 5% CO 2 /95% O 2 , pH of 7.4. Each tissue strip was incrementally stretched to optimal isometric tension, as determined by maximal contractile response to 1 µM phenylephrine. Then each tissue was given 0.5 µM phenylephrine, and the phophodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX; 100 µM) and allowed to incubate for 15 minutes; after which time tissues were treated with drug or vehicle. Tissues were allowed to incubate for another 5 minutes then immediately frozen in liquid nitrogen and stored at -80ºC until extraction for cyclic nucleotide assay. Tissues were extracted by homogenization in 6% trichloroacetic acid followed by ether (H 2 O-saturated) extraction and lyophilization. Cyclic AMP was determined by ELISA using a kit from Cayman Chemical Co. (Ann Arbor, MI).
Protein determinations.
Proteins were determined using the Bio-Rad Protein Assay Kit microtiter plate assay procedure (Bio-Rad, Hercules, CA) with bovine serum albumin as standard.
Drugs and Materials.
Arachidonic acid, indomethacin, phenylephrine, acetylcholine chloride, 9,11-dideoxy-9α,11α-epoxymethano PGF 2α (U46619), 3-isobutyl-1-methylxanthine (IBMX) and phorbol 12,13-dibutyrate (PDBu) were obtained from Sigma Chemical Co. (St. Louis, MO). Prostaglandin E 1 (alprostadil) was obtained from Pharmacia (Barcelona, Spain). Prostaglandin E 0 (13, 14 dehydro-PGE 1 ) was purchased from Cayman Chemical (Ann Arbor, MI). [1S-[1α,2α(Z) International (Natick, MA). Bisindoleyl-maleimide I (GF109203X; 3-[1-[3-(Dimethylamino) propyl]1H-indol-3-yl]-4-(1H-indol-3-yl)1H-pyrrole-2,5dione) was obtained from Alexis (Lausen, Switzerland). Prostanoid derivatives were dissolved at 10 mM concentration in ethanol and GF109203X was dissolved in dimethyl sulfoxide (DMSO) at 10 mM concentration (final concentration of DMSO was 0.0001%). Dilutions were made in distilled water at the time of the experiment. Non-prostanoid drugs were dissolved in distilled water.
Indomethacin was dissolved in 1.5 mM Na 2 CO 3 .
Data analysis
Contractile effects produced by drugs are expressed as the percentage of 
Relaxation of human corpus cavernosum tissue induced by arachidonic acid.
Addition of arachidonic acid (AA; 100 µM) produced a relaxant response in human corpus cavernosum strips that was prevented by incubation with the cyclooxygenase inhibitor indomethacin (5 µM), in accordance with previous observations (Angulo et al., 2002) . This relaxation was significantly impaired in tissues from diabetic patients. Treatment of diabetic tissues with the TPreceptor blocker, SQ29548 (20 nM) caused a full recovery of AA-induced relaxation ( Fig. 1 ).
Relaxant responses elicited by PGE 1 and PGE 0 in human corpus cavernosum tissue.
The active metabolite of PGE 1 , PGE 0 , relaxed corpus cavernosum tissue, but this relaxant response was reduced when compared to that induced by its parent molecule ( Fig. 2A ). PGE 0 (1 µM), however, produced an increase of cAMP content in human cavernosal tissue similar to that obtained with PGE 1 at the same concentration (Fig. 2B ). The treatment of cavernosal tissue with SQ29548 (20 nM) did not modify relaxation induced by PGE 1 (data not shown),
but significantly improved the relaxant responses evoked by PGE 0 (Fig. 2C ).
Indeed, treatment with SQ29548 abolished the differences between PGE 1 -and PGE 0 -induced relaxations (Fig. 2D ).
Influence of diabetes on the relaxation of human corpus cavernosum to PGE 1 and PGE 0
The relaxations induced by PGE 1 in corpus cavernosum tissues from diabetic patients were not different from those obtained in tissues from nondiabetic patients (Fig. 3A) . In contrast, the responses to PGE 0 were significantly impaired in tissues from diabetic patients (Fig. 3B ). This impairment was reversed by treating the tissues with the TP receptor blocker, SQ29548 (20 nM) (Fig. 3C ).
Effect of diabetes and TP-receptor blockade on endothelium dependentrelaxation of human corpus cavernosum.
Human corpus cavernosum strips were relaxed by the cumulative addition of acetylcholine (ACh; 1 nM to 10 µM). The ACh-induced relaxation in this tissue was significantly impaired by diabetes. Treatment with SQ29548 (20 nM) did not alter endothelium-dependent relaxation of cavernosal strips from non diabetic patients, but significantly improved ACh-induced relaxation in corpus cavernosum from diabetic patients. However, SQ29548 was not able to completely recover endothelium-dependent relaxation in diabetic tissues (Fig. 4;  in non diabetic patients, precontraction values were 2.40±0.74 and 2.43±1.01
for control and SQ29548, respectively; in diabetic patients, precontraction values were 2.14±0.67 g and 2.41±0.75 g for control and SQ29548, respectively. Not significant).
Effects of modulation of PKC activity on endothelium-dependent relaxation of corpus cavernosum from diabetic and non-diabetic patients.
The inhibition of PKC activity with GF109203X (1 µM) significantly (1 µM) ( Fig. 6B ; precontraction values were 2.60±1.02 g and 2.76±0.95 g for control and PDBu plus GF109203X, respectively. Not significant).
Effects of diabetes and PKC inhibition on the contraction of human corpus cavernosum mediated by TP receptors
The thromboxane analogue, U46619, produced concentration-dependent contractions of HCC smooth muscle. Tissues from diabetic patients showed enhanced sensitivity to U46619 compared to tissues from non-diabetic patients ( did not alter U46619-induced contractions in corpus cavernosum tissue from non diabetic patients, but significantly inhibited these responses in cavernosal tissue from diabetic patients. In fact, treatment with GF109203X completely prevented the hypersensitive contractile responses to U46619 of diabetic tissues (Fig. 7A ). Neither diabetes nor PKC inhibition significantly affected maximal contractile response to U46619 (Fig. 7B ).
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